The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study.
Cecilia A CastellanoTianyi SunDeepak RavindranathanClara HwangNino BalanchivadzeSunny R K SinghElizabeth A GriffithsIgor PuzanovErika Ruiz-GarciaDiana Vilar-CompteAna I Cárdenas-DelgadoRana R McKayTaylor K NonatoArchana AjmeraPeter Paul YuRajani NadkarniTimothy E O'ConnorStephanie A BergKim MaDimitrios FarmakiotisKendra VieiraPanos ArvanitisRenee M SalibyChris LabakiAmin H NassarTrisha M Wise-DraperOlga ZamulkoNingjing LiBrianne E BodinMelissa K AccordinoMatthew InghamMonika JoshiHyma V PolimeraLeslie A FecherChristopher R FrieseJames J YoonBlanche H MavromatisJacqueline T BrownKaren RussellRahul S NanchalHarpreet SinghLisa TachikiFeras A MoriaGayathri NagarajKimberly CortezSaqib H AbbasiElizabeth M Wulff-BurchfieldMatthew PucLisa B WeissmannPadmanabh S BhattMelissa G MarianoSanjay MishraSusan HalabiAlicia BeeghlyJeremy L WarnerBenjamin FrenchMehmet Asim Bilennull nullPublished in: Cancer (2024)
Patients with metastatic cancer, especially with metastasis to the brain, are more likely to have severe outcomes after COVID-19 whereas patients with metastasis to the lung, compared to patients with cancer metastasis to other sites, have the highest 30-day mortality after COVID-19.